What are the drug interactions for both dihydropyridine calcium‑channel blockers (e.g., amlodipine, felodipine, lercanidipine) and non‑dihydropyridine calcium‑channel blockers (diltiazem, verapamil)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 23, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Medication Interactions with Calcium Channel Blockers

The most clinically significant drug interactions differ markedly between dihydropyridine CCBs (amlodipine, felodipine, lercanidipine) and non-dihydropyridine CCBs (diltiazem, verapamil), with non-dihydropyridines causing substantially more dangerous interactions due to their potent CYP3A4 inhibition.

Non-Dihydropyridine CCBs (Diltiazem, Verapamil): High-Risk Interactions

Statins - CRITICAL INTERACTION

Diltiazem and verapamil are moderate-to-weak CYP3A4 inhibitors that dramatically increase statin exposure, creating significant rhabdomyolysis risk 1:

  • Simvastatin: Diltiazem increases AUC by 5-fold and Cmax by 3.6-fold. Maximum dose: 10 mg daily with diltiazem or verapamil 1
  • Lovastatin: Diltiazem increases AUC by 3.6-fold. Maximum dose: 20 mg daily with diltiazem; 40 mg daily with verapamil (though verapamil labeling permits 40 mg) 1
  • Atorvastatin: Minor increase in exposure; combination is reasonable but rhabdomyolysis has been reported when diltiazem was added 1
  • Preferred strategy: Switch to non-CYP3A4 metabolized statins (pravastatin, rosuvastatin, pitavastatin) when initiating diltiazem or verapamil 1

Digoxin

Verapamil increases digoxin levels by >50%, requiring dose reduction and monitoring 2, 3. Diltiazem also increases digoxin concentrations but to a lesser extent 3.

Beta-Blockers

Both diltiazem and verapamil can potentiate beta-blocker effects, causing excessive bradycardia, heart block, and negative inotropy 2, 3. This combination requires careful monitoring, particularly in patients with pre-existing conduction abnormalities.

Immunosuppressants

  • Cyclosporine: Diltiazem increases trough levels by ~40% 4
  • Tacrolimus: Potential 2.5-4 fold increase in exposure, particularly in CYP3A5 expressers 4

Antiarrhythmics

Additive effects on cardiac conduction with drugs like quinidine and disopyramide increase risk of heart block 2.

Dihydropyridine CCBs (Amlodipine, Felodipine, Lercanidipine): Lower-Risk Profile

Statins - MODERATE INTERACTION

Amlodipine is a weak CYP3A4 inhibitor with clinically relevant interactions only at higher statin doses 1, 4:

  • Simvastatin: Amlodipine increases exposure by 77%. Maximum dose: 20 mg daily with amlodipine 1, 4
  • Lovastatin: Minor increase in exposure. Maximum dose: 20 mg daily with amlodipine 1
  • Atorvastatin, pitavastatin, rosuvastatin, fluvastatin, pravastatin: No significant interaction; combination may be used without restriction 1

Immunosuppressants

  • Cyclosporine: Amlodipine increases trough levels by ~40% 4
  • Tacrolimus: 2.5-4 fold increase possible in CYP3A5 expressers; 3-fold increase reported in non-expressers 4

Digoxin

Amlodipine does not affect digoxin exposure 4, unlike non-dihydropyridines.

CYP3A4 Inhibitors Affecting Dihydropyridines

Strong CYP3A4 inhibitors (itraconazole, clarithromycin, ritonavir) increase dihydropyridine levels 4, 5:

  • Diltiazem increases amlodipine exposure by 60% 4
  • Grapefruit juice, cimetidine, and antacids have no significant effect 4

P-Glycoprotein Interactions

Nifedipine, nitrendipine, and felodipine inhibit P-gp, potentially increasing digoxin levels 5. Lercanidipine and amlodipine have minimal P-gp effects 5.

Key Mechanistic Differences

Non-dihydropyridines (diltiazem, verapamil) 6:

  • Form quasi-irreversible metabolite-intermediate complexes with CYP3A4
  • Cause potent, sustained enzyme inhibition
  • Affect cardiac conduction (negative chronotropic/dromotropic effects)

Dihydropyridines (amlodipine, felodipine, lercanidipine) 5, 6:

  • Weak, reversible CYP3A4 inhibition
  • Minimal cardiac conduction effects
  • Primarily vascular selectivity

Critical Clinical Pitfalls

  1. Asian patients: Exercise heightened caution with all statin-CCB combinations due to increased susceptibility to myopathy 1

  2. Switching from simvastatin 80 mg: If initiating diltiazem or verapamil, immediately switch to pravastatin, rosuvastatin, or pitavastatin 1

  3. Bradycardia/heart block: Non-dihydropyridines are contraindicated in patients with sinus or AV nodal disease 3, 7

  4. Vasodilator combinations: All CCBs can cause additive hypotension with other vasodilators 5

  5. Sildenafil: Amlodipine and sildenafil independently lower blood pressure; monitor for excessive hypotension 4

References

Related Questions

In an 87-year-old female with uncontrolled hypertension who is taking a calcium‑channel blocker at 60 mg and has peripheral edema, and who wishes to reduce the dose to 30 mg, what additional antihypertensive medication should be added to achieve better blood pressure control?
When should a dihydropyridine calcium‑channel blocker be preferred over a non‑dihydropyridine calcium‑channel blocker for treating hypertension?
What is the calcium channel blocker scoring system for selecting appropriate antihypertensive therapy and how is it applied?
Does Amlodipine (calcium channel blocker) cause fluid retention?
What is the best anti-hypertensive medication for a patient with pulsatile tinnitus caused by hypertension, considering potential underlying kidney or cardiovascular disease?
In a 21-year-old man with persistent semi‑erections, glans discoloration, penile numbness, and urinary hesitancy, can the cavernous artery Doppler ultrasound be performed without pharmacologically inducing an erection?
Can acetaminophen (Tylenol) be taken together with phenazopyridine (Azo)?
When should a dihydropyridine calcium‑channel blocker be preferred over a non‑dihydropyridine calcium‑channel blocker for treating hypertension?
What medication adjustments are recommended for a 57-year-old male with hypertension, chronic suicidal ideation, ADHD, depression, and anxiety who is taking guanfacine extended‑release 1 mg, bupropion XL 450 mg, and escitalopram 20 mg but continues to have ADHD symptoms and suicidal thoughts?
Can I prescribe 100 mg of intravenous tramadol every eight hours for an adult patient?
What is the increase in breast cancer risk associated with menopausal hormone replacement therapy (HRT)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.